MIRAPEXIN Tablet / Prolonged-release tablet (2018)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
MIRAPEXIN 0.088 mg tablets. MIRAPEXIN 0.18 mg tablets. MIRAPEXIN 0.35 mg tablets. MIRAPEXIN 0.7 mg tablets. MIRAPEXIN 1.1 mg tablets.
Qualitative and quantitative composition
MIRAPEXIN 0.088 mg tablets: Each tablet contains 0.125 mg pramipexole dihydrochloride monohydrate equivalent to 0.088 mg pramipexole. MIRAPEXIN 0.18 mg tablets: Each tablet contains 0.25 mg pramipexole ...
Pharmaceutical form
Tablet. MIRAPEXIN 0.088 mg tablets: The tablets are white, flat, of round shape, and have a code embossed (one side with the code P6, and one side with the Boehringer Ingelheim company symbol). MIRAPEXIN ...
Therapeutic indications
MIRAPEXIN is indicated in adults for treatment of the signs and symptoms of idiopathic Parkinsons disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, ...
Posology and method of administration
Posology Parkinsons disease The daily dose is administered in equally divided doses 3 times a day. Initial treatment Doses should be increased gradually from a starting dose of 0.264 mg of base (0.375 ...
Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Special warnings and precautions for use
When prescribing MIRAPEXIN in a patient with Parkinsons disease with renal impairment a reduced dose is suggested in line with section 4.2. Hallucinations Hallucinations are known as a side effect of treatment ...
Interaction with other medicinal products and other forms of interaction
Plasma protein binding Pramipexole is bound to plasma proteins to a very low (<20%) extent, and little biotransformation is seen in man. Therefore, interactions with other medicinal products affecting ...
Fertility, pregnancy and lactation
Pregnancy The effect on pregnancy and lactation has not been investigated in humans. Pramipexole was not teratogenic in rats and rabbits, but was embryotoxic in the rat at maternotoxic doses (see section ...
Effects on ability to drive and use machines
MIRAPEXIN can have a major influence on the ability to drive and use machines. Hallucinations or somnolence can occur. Patients being treated with MIRAPEXIN and presenting with somnolence and/or sudden ...
Undesirable effects
Based on the analysis of pooled placebo-controlled trials, comprising a total of 1,923 patients on pramipexole and 1,354 patients on placebo, adverse drug reactions were frequently reported for both groups. ...
Overdose
There is no clinical experience with massive overdose. The expected adverse reactions would be those related to the pharmacodynamic profile of a dopamine agonist, including nausea, vomiting, hyperkinesia, ...
Pharmacodynamic properties
Pharmacotherapeutic group: Anti-Parkinson drugs, dopamine agonists ATC code: N04BC05 Mechanism of action Pramipexole is a dopamine agonist that binds with high selectivity and specificity to the D<sub> ...
Pharmacokinetic properties
Absorption Pramipexole is rapidly and completely absorbed following oral administration. The absolute bioavailability is greater than 90% and the maximum plasma concentrations occur between 1 and 3 hours. ...
Preclinical safety data
Repeated dose toxicity studies showed that pramipexole exerted functional effects, mainly involving the CNS and female reproductive system, and probably resulting from an exaggerated pharmacodynamic effect ...
List of excipients
Mannitol Maize starch Anhydrous colloidal silica Povidone K25 Magnesium stearate
Incompatibilities
Not applicable.
Shelf life
3 years.
Special precautions for storage
Do not store above 30°C. Store in the original package in order to protect from light.
Nature and contents of container
OPA/aluminium/PVC-aluminium blisters. Each blister strip contains 10 tablets. Cartons containing 3 or 10 blister strips (30 or 100 tablets). Not all pack sizes may be marketed.
Special precautions for disposal and other handling
No special requirements.
Marketing authorization holder
Boehringer Ingelheim International GmbH, Binger Strasse 173, D-55216 Ingelheim am Rhein, Germany
Marketing authorization number(s)
MIRAPEXIN 0.088 mg tablets: EU/1/97/051/001-002 MIRAPEXIN 0.18 mg tablets: EU/1/97/051/003-004 MIRAPEXIN 0.35 mg tablets: EU/1/97/051/011-012 MIRAPEXIN 0.7 mg tablets: EU/1/97/051/005-006 MIRAPEXIN 1.1 ...
Date of first authorization / renewal of the authorization
Date of first authorisation: 23 February 1998 Date of latest renewal: 23 February 2008
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:
